Table II.
Treatment outcome for patients with EGFR-mutant advanced non-small cell lung cancer receiving EGFR tyrosine kinase inhibitors.
| PFS | OS | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| ORR | Univariate | Multivariate | Univariate | Multivariate | |||||||
| Variable | No., % | No., % | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value |
| Concomitant alternation status | 0.07 | 0.04a | 0.047a | 0.01a | 0.03a | ||||||
| Not detected | 13 (31.7) | 12 (92.3) | 2.14 (95% CI, 1.03–4.44) | 2.30 (1.01–5.23) | 4.30 (1.41–13.16) | 9.20 (1.18–71.50) | |||||
| Detected | 28 (68.3) | 18 (64.3) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | |||||
| Smoking status | 0.48 | 0.04a | 0.10 | 0.04a | 0.13 | ||||||
| No | 26 (63.4) | 20 (76.9) | 2.02 (0.86–4.76) | 2.71 (0.83–8.87) | 2.87 (0.87–9.53) | 3.95 (0.74–21.10) | |||||
| Yes | 15 (36.6) | 10 (66.7) | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | |||||
a
P<0.05. EGFR, epidermal growth factor receptor; ORR, objective response rate; PFS, progression-free survival; OS, overall survival; HR, hazard ratio; NR, not reached.